Your browser doesn't support javascript.
loading
Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets.
Tóvári, József; Vári-Mezo, Diána; Surguta, Sára Eszter; Ladányi, Andrea; Kigyós, Attila; Cserepes, Mihály.
Affiliation
  • Tóvári J; Department of Experimental Pharmacology, National Institute of Oncology, 1122 Budapest, Hungary.
  • Vári-Mezo D; National Tumor Biology Laboratory, National Institute of Oncology, 1122 Budapest, Hungary.
  • Surguta SE; Department of Experimental Pharmacology, National Institute of Oncology, 1122 Budapest, Hungary.
  • Ladányi A; National Tumor Biology Laboratory, National Institute of Oncology, 1122 Budapest, Hungary.
  • Kigyós A; Department of Experimental Pharmacology, National Institute of Oncology, 1122 Budapest, Hungary.
  • Cserepes M; National Tumor Biology Laboratory, National Institute of Oncology, 1122 Budapest, Hungary.
Cells ; 12(14)2023 07 24.
Article in En | MEDLINE | ID: mdl-37508582
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proto-Oncogene Proteins B-raf / Vemurafenib / Melanoma Limits: Animals / Humans Language: En Journal: Cells Year: 2023 Type: Article Affiliation country: Hungary
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proto-Oncogene Proteins B-raf / Vemurafenib / Melanoma Limits: Animals / Humans Language: En Journal: Cells Year: 2023 Type: Article Affiliation country: Hungary